Business
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
JERSEY CITY, N.J., February 27, 2026--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/ed0fd7f83d50d900039cbf55a3b56b57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OcMib0_ZK3d2ZQKe.Xb.4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ed0fd7f83d50d900039cbf55a3b56b57","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OL9i5sHU6Rmw_S3vlC7U4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ed0fd7f83d50d900039cbf55a3b56b57","width":1200,"height":180}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8","length":233,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":233,"olType":false},{"type":"text","content":"JERSEY CITY, N.J., February 27, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, on February 27, 2026. The findings show that VTAMA cream provided early and consistent improvements in the POEM sleep subdomain for pediatric patients down to age 2 with moderate to severe atopic dermatitis (AD) and in the DFI sleep subdomain for family members of patients aged 2-15 years.","length":750,"tagName":"p"},{"type":"text","content":""Sleep disturbance is a significant problem for children with atopic dermatitis and their families, and one that I always take time to address in my clinic," said Dr. Mark Boguniewicz, Professor in the Department of Pediatrics, Division of Allergy and Immunology at National Jewish Health and the University of Colorado School of Medicine, and an author of the analysis being presented at the AAAAI meeting. &...